Procept Biorobotics Corporation has announced the successful completion of three prostate cancer procedures as part of the WATER IV Prostate Cancer (PCa) Trial at an Ambulatory Surgery Center using Aquablation® therapy. Conducted by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona, the procedures were completed without complications, allowing for same-day patient discharge. The WATER IV PCa trial is a U.S. FDA investigational device exemption $(IDE)$ approved study comparing the safety and efficacy of Aquablation therapy and radical prostatectomy in treating localized prostate cancer. The trial aims to evaluate a minimally invasive approach that utilizes a robotically-controlled waterjet for tissue resection. Results of the trial are anticipated to be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.